IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment | SpinGraph: Adoption momentum
SpinGraph analysis of PR Newswire Technology's IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk B…
Know the moment AI knows your story. Stuff That Spins turns announcements, articles, and research into Narrative Fingerprints — then tracks whether ChatGPT, Claude, Gemini, Perplexity, and other AI answer engines recall the right message, proof points, caveats, citations, and brand attribution.
IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment
cryoablation, ChoICE Study, Adventist Health Glendale
Adventist Health Glendale is now the first U.S. site enrolling patients in IceCure’s ChoICE Study The site is led by Dr. Dennis Holmes, a recognized cryoablation surgeon This marks a clinical deployment milestone following regulatory clearance
Emphasizes procedural progress (IRB approval, site activation) while minimizing absence of outcome data, study design transparency, or comparative benchmarks.
IceCure Medical's ChoICE Study has begun enrolling patients in the U.S. at Adventist Health Glendale, marking its first U.S. clinical site.
No mention of study size, duration, endpoints, comparator arms, or prior trial results; No indication of patient eligibility criteria or inclusion/exclusion thresholds
It combines institutional credibility signals (Adventist Health, IRB approval, named surgeon) with temporal language ('first') to imply forward motion and inevitability, making the modest procedural milestone feel like clinical validation — despite zero presentation of efficacy, safety, or comparative performance data.
Adventist Health Glendale is the first U.S. site able to enroll patients in the ChoICE Study after signing both an agreement and receiving IRB approval.
Adventist Health Glendale is the first site able to enroll patients in the ChoICE Study after signing both an agreement and receiving IRB approval
Extracted statistics from the source narrative
Indicates initial geographic expansion of post-market study